NCT02784002View on ClinicalTrials.gov

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Clostridium Difficile Infection
Interventions
DRUG

Ridinilazole

DRUG

Fidaxomicin

Trial Locations (16)

59701

Butte, Butte

83404

Idaho, Idaho Falls

92653

Laguna Hills, Laguna Hills

93003

Ventura, Ventura

08244

New Jersey, Somers Point

Unknown

Liberec, Liberec

Pardubice, Pardubice

Praha, Prague

Zlin, Zlín

Leeds, Leeds

Liverpool, Liverpool

London, London

Manchester, Manchester

Newcastle Upon Tyne, Newcastle upon Tyne

Oxford, Oxford

Wigan, Wigan

Sponsors
All Listed Sponsors
lead

Summit Therapeutics

INDUSTRY

NCT02784002 - A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) | Biotech Hunter | Biotech Hunter